MEDIROM Healthcare Technologies Inc. American Depositary Share (MRM)

FairStock Score: 50/100 — MIXED

Key Financials

Strengths

• Generates $313 million in annual free cash flow (3337.6% yield on market cap)
• High return on equity of 53.2% demonstrating efficient capital deployment

Concerns

• High leverage at 7.86x debt-to-equity increases financial risk and interest expense burden
• Weak Piotroski F-Score of 0/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of -0.2 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

MEDIROM Healthcare Technologies Inc. American Depositary Share is a micro-cap consumer cyclical company valued at $9 million. Revenue stands at $8.1 billion. From a quality standpoint, MEDIROM shows weak Piotroski F-Score of 0/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -0.2 warrants caution. On valuation, the stock is deeply undervalued on a P/E basis at 3.0x, with offers a 96% margin of safety vs Graham Number of $32. Our composite FairStock Score of 50/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

The market underappreciates MEDIROM's consistent 53% ROE at just 3x earnings—a re-rating toward sector peers could unlock 30-50% upside. With $313 million in annual free cash flow (3337.6% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Elevated leverage at 7.9x D/E means rising interest rates or revenue weakness could strain debt covenants and force asset sales at distressed prices. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer